GB2491539A - Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome - Google Patents
Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome Download PDFInfo
- Publication number
- GB2491539A GB2491539A GB1218050.1A GB201218050A GB2491539A GB 2491539 A GB2491539 A GB 2491539A GB 201218050 A GB201218050 A GB 201218050A GB 2491539 A GB2491539 A GB 2491539A
- Authority
- GB
- United Kingdom
- Prior art keywords
- glucose metabolism
- birt
- hogg
- treatment
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003112 inhibitor Substances 0.000 title abstract 7
- 230000004153 glucose metabolism Effects 0.000 title abstract 5
- 208000033929 Birt-Hogg-Dubé syndrome Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 abstract 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 abstract 1
- 230000002414 glycolytic effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A composition comprising an inhibitor of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome. The inhibitor of glucose metabolism may be a glycolytic inhibitor. The inhibitor of glucose metabolism may be an inhibitor of pyruvate metabolism. Suitable inhibitors of glucose metabolism include 2-deoxy-D- glucose or a pharmaceutically acceptable salt or solvate thereof or oxamate or a pharmaceutically acceptable salt or solvate thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1003894A GB2478556A (en) | 2010-03-09 | 2010-03-09 | A composition for use in the treatment of Birt-Hogg-Dubô sydrome |
PCT/GB2011/050454 WO2011110842A2 (en) | 2010-03-09 | 2011-03-08 | Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201218050D0 GB201218050D0 (en) | 2012-11-21 |
GB2491539A true GB2491539A (en) | 2012-12-05 |
Family
ID=42136701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1003894A Withdrawn GB2478556A (en) | 2010-03-09 | 2010-03-09 | A composition for use in the treatment of Birt-Hogg-Dubô sydrome |
GB1218050.1A Withdrawn GB2491539A (en) | 2010-03-09 | 2011-03-08 | Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1003894A Withdrawn GB2478556A (en) | 2010-03-09 | 2010-03-09 | A composition for use in the treatment of Birt-Hogg-Dubô sydrome |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2544678A2 (en) |
GB (2) | GB2478556A (en) |
WO (1) | WO2011110842A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021007499A1 (en) * | 2019-07-11 | 2021-01-14 | Emory University | Combination therapies for managing cancer |
WO2021251842A1 (en) * | 2020-06-08 | 2021-12-16 | Qatar Foundation For Education, Science And Community Development | Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062604A2 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
WO2004064734A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
PT2131821T (en) * | 2007-03-07 | 2018-10-10 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
JP2012506898A (en) * | 2008-10-31 | 2012-03-22 | ノバルティス アーゲー | Combination of phosphatidylinositol-3-kinase (PI3K) inhibitor and mTOR inhibitor |
-
2010
- 2010-03-09 GB GB1003894A patent/GB2478556A/en not_active Withdrawn
-
2011
- 2011-03-08 EP EP11709454A patent/EP2544678A2/en not_active Withdrawn
- 2011-03-08 WO PCT/GB2011/050454 patent/WO2011110842A2/en active Application Filing
- 2011-03-08 GB GB1218050.1A patent/GB2491539A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062604A2 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
WO2004064734A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
Non-Patent Citations (4)
Title |
---|
ANNUAL REVIEW OF MEDICINE, Vol. 61, 2010, W. MARSTON LINEHAN ET AL: "Molecular Diagnosis and Therapy of Kidney Cancer", Pages 329-343 * |
CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENECE PUBLISHING, Vol. 180, 2008, YANG ET AL: "The UOK 257 cell line: a novel model for studies of the human....", Pages 100-109 * |
INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, Vol. 24, 2006, JACQUELINE VUKY ET AL: "Phase II trial of imatinib (Gleevec(R)) in patients with metastatic renal cell carcinoma", Pages 85-88 * |
ONCOGENE, Vol. 25, 2006, H PELICANO ET AL: "Glycolysis inhibition for anticancer treatment", Pages 4633-4646 * |
Also Published As
Publication number | Publication date |
---|---|
GB201003894D0 (en) | 2010-04-21 |
GB2478556A (en) | 2011-09-14 |
WO2011110842A3 (en) | 2012-05-10 |
WO2011110842A2 (en) | 2011-09-15 |
EP2544678A2 (en) | 2013-01-16 |
GB201218050D0 (en) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012214029A8 (en) | Rorgammat inhibitors | |
UA98141C2 (en) | Methods of treating with quinaxoline inhibitors of pi3k-alpha | |
WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
HK1139863A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
IL210494A (en) | Organic compounds as smo inhibitors and pharmaceutical compositions comprising them for use in the treatment of cancer | |
EP2558035A4 (en) | Systems and methods for tensioning ligaments and other soft tissues | |
IL216383A0 (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
MX2010010300A (en) | Mtor inhibitor salt forms. | |
HK1125831A1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
EP2434010A4 (en) | Prophylactic and/or therapeutic agent for metabolic syndrome | |
IL199829A0 (en) | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | |
EP2395980A4 (en) | Compositions and methods for treating post-operative pain using bupivacaine and an anti-inflammatory agent | |
EP2756764A4 (en) | Sweetener composition for preventing and improving obesity, containing glycolysis inhibitor ingredient | |
MX2013006319A (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer. | |
GB201105050D0 (en) | Pharmaceutical agent | |
TN2012000242A1 (en) | Heterocyclic sulfonamide derivatives | |
WO2012064396A3 (en) | Novel ezrin inhibitors and methods of making and using | |
MX2013014398A (en) | Heterocyclic sulfonamide derivatives. | |
TR201900438T4 (en) | Non-acylated ghrelin fragments for use in the treatment of Prader-willi syndrome. | |
EP3406242B8 (en) | Tlr4 antagonist for use in the treatment of increased ammonia plasma levels | |
GB2491539A (en) | Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome | |
EP2324852A4 (en) | Therapeutic or prophylactic agent for generalized pain syndrome | |
IL182055A0 (en) | Agent for prophylaxis or treatment of metabolic syndrome | |
MY173722A (en) | Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome | |
NZ717880A (en) | Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |